Systemic Therapy of Advanced Renal Cell Carcinoma—Summary of Main Presentations at the ASCO, ASCO-GU and ESMO 2012 Annual Meetings

Andres Jan Schrader

Department of Urology, Ulm Medical Center, Ulm, Germany.

DOI: 10.4236/oju.2013.31002                

Abstract

A number of very interesting studies presented this year at the ASCO (American Society of Clinical Oncology) Annual Meeting, the ASCO-GU (ASCO Genitourinary Cancers) Spring Meeting, and the ESMO (European Society for Medical Oncology) Annual Congress could strongly influence or even revolutionize the systemic treatment of advanced renal cell carcinoma (RCC). The aim of this article is to identify, summarize and discuss some outstanding studies of direct or indirect clinical relevance for systemic therapy.

Keywords

Renal Cell Carcinoma; ASCO; ESMO; Review; Systemic Therapy

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. J. Schrader and S. Steffens, “Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011,” ISRN Urology, Vol. 2012, 2012, Article ID: 748235. doi:10.5402/2012/748235
[2]	A. J. Schrader, S. Steffens, T. J. Schnoeller, M. Schrader and M. A. Kuczyk, “Neoadjuvant Therapy of Renal Cell Carcinoma: A Novel Treatment Option in the Era of Targeted Therapy?” International Journal of Urology, Vol. 19, No. 10, 2012, pp. 903-907. doi:10.1111/j.1442-2042.2012.03065.x
[3]	U. Harmenberg, S. Lundstam, T. Wahlgren, J. Kowalski, M. Jakobsson, R. Sandin, B. Ljungberg and P. Sandstrom, “Treatment and Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC): A Swedish Population-Based Study (2000-2008),” Journal of Clinical Oncology, Vol. 30, Suppl. 5, 2012, Abstract No. 389.
[4]	D. Y. Heng, W. Xie, M. M. Regan, T. Cheng, S. North, J. J. Knox, C. Kollmannsberger, D. McDermott, B. I. Rini and T. K. Choueiri, “Prognostic Factors for Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (RCC) Treated with Vascular Endothelial Growth Factor (VEGF)-Targeted Agents: Results from a Large Multicenter Study,” Journal of Clinical Oncology, Vol. 27, No. 34, 2009, pp. 5794-5799.
[5]	M. Schmidinger, C. C. Zielinski, U. M. Vogl, A. Bojic, M. Bojic, C. Schukro, M. Ruhsam, M. Hejna and H. Schmidinger, “Cardiac Toxicity of Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 26, No. 32, 2008, pp. 5204-5212. doi:10.1200/JCO.2007.15.6331
[6]	M. Schmidinger, U. M. Vogl, C. Schukro, A. Bojic, M. Bojic, H. Schmidinger and C. C. Zielinski, “Cardiac Involvement in Patients with Sorafenib or Sunitinib Treatment for Metastatic Renal Cell Carcinoma,” Journal of Clinical Oncology, Vol. 25, No. 18S, 2007, Abstract No. 5110.
[7]	P. S. Hall, R. Witteles, S. Srinivas and L. C. Harshman, “Incidence and Severity of Cardiotoxicity in Metastatic Renal Cell Carcinoma (RCC) Patients Treated with Targeted Therapies,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4610.
[8]	N. B. Haas, J. Manola, B. Ky, K. T. Flaherty, R. Uzzo, C. G. Wood, C. J. Kane, M. A. S. Jewett, M. B. Atkins, J. P. Dutcher and R. S. DiPaola, “Cardiac Safety Analysis for a Phase III Trial of Sunitinib (SU) or Sorafenib (SO) or Placebo (PLC) in Patients (pts) with Resected Renal Cell Carcinoma (RCC),” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4500.
[9]	R. J. Motzer, D. Nosov, T. Eisen, I. N. Bondarenko, V. Lesovoy, O. N. Lipatov, P. Tomczak, A. A. Lyulko, A. Alyasova, M. Harza, M. Kogan, B. Y. Alexeev, C. N. Sternberg, C. Szczylik, J. Zhang, A. L. Strahs, B. Esteves, W. J. Slichenmyer, A. Berkenblit and T. E. Hutson, “Tivozanib versus Sorafenib as Initial Targeted Therapy for Patients with Advanced Renal Cell Carcinoma: Results from a Phase III Randomized, Open-Label, Multicenter Trial,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4501.
[10]	B. I. Rini, V. Gruenwald, M. N. Fishman, B. Melichar, T. Ueda, P. A. Karlov, A. H. Bair, Y. Chen, S. Kim and E. Jonasch, “Axitinib for First-Line Metastatic Renal Cell Carcinoma (mRCC): Overall Efficacy and Pharmacokinetic (PK) Analyses from a Randomized Phase II Study,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4503.
[11]	B. I. Rini, B. Escudier, P. Tomczak, A. Kaprin, T. E. Hutson, C. Szczylik, J. C. Tarazi, B. Rosbrook, S. Kim and R. J. Motzer, “Axitinib versus Sorafenib as Second-Line Therapy For Metastatic Renal Cell Carcinoma (mRCC): Results of Phase III AXIS Trial.,” Journal of Clinical Oncology, Vol. 29, Suppl. 15, 2011, Abstract No. 4503.
[12]	M. Staehler, N. Haseke, T. Stadler, K. Zilinberg, C. Nordhaus, M. Dieckmann, P. Nuhn and C. G. Stief, “Intraindividual Sorafenib Dose Escalation in the Treatment of Metastatic Clear Cell Renal Cell Carcinoma (mRCC),” Annual Meeting of the German Society for Urology (DGU), Vol. 61, 2009, Abstract No. P 6.10.
[13]	R. J. Amato, J. Jac, P. Harris, M. Dalton, S. Saxena, F. Monzon, J. Zhai, J. Brady and J. P. Willis, “A Phase II Trial of Intra-Patient Dose Escalated-Sorafenib in Patients (pts) with Metastatic Renal Cell Cancer (MRCC),” Journal of Clinical Oncology, Vol. 26, No. 15S, 2008, Abstract No. 5122.
[14]	C. Szczylik, T. Demkow, M. Staehler, F. Rolland, S. Negrier, T. E. Hutson, R. M. Bukowski, U. J. Scheuring, K. Burk and B. Escudier, “Randomized Phase II Trial of First-Line Treatment with Sorafenib Versus Interferon in Patients with Advanced Renal Cell Carcinoma: Final Results,” Journal of Clinical Oncology, Vol. 25, No. 18S, 2007, Abstract No. 5025.
[15]	I. Puzanov, J. A. Sosman, A. Santoro, R. E. Martell, G. K. Dy, L. Williams Goff, W. W. Ma, G. J. Fetterly, S. A. Michael, J. A. Means-Powell, F. Chai, M. Lamar, G. M. Strauss, P. A. Zucali, W. M. Chiang, J. Jarboe, B. E. Schwartz and A. A. Adjei, “Safety and Efficacy of MET Inhibitor Tivantinib (ARQ 197) Combined with Sorafenib in Patients (pts) with Renal Cell Carcinoma (RCC) from a Phase I Study,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4545.
[16]	T. K. Choueiri, S. K. Pal, D. F. McDermott, D. A. Ramies, S. Morrissey, Y. Lee, D. Miles, J. Holland and J. P. Dutcher, “Efficacy of Cabozantinib (XL184) in Patients (pts) with Metastatic, Refractory Renal Cell Carcinoma (RCC),” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4504.
[17]	M. R. Smith, C. Sweeney, D. E. Rathkopf, H. I. Scher, C. Logothetis, D. J. George, C. S. Higano, E. Y. Yu, A. L. Harzstark, E. J. Small, A. O. Sartor, M. S. Gordon, N. J. Vogelzang, D. C. Smith, M. Hussain, J. S. De Bono, N. B. Haas, C. Scheffold, Y. Lee and P. G. Corn, “Cabozantinib (XL184) in Chemotherapy-Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): Results from a Phase II Nonrandomized Expansion Cohort (NRE),” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4513.
[18]	M. E. Cabanillas, M. S. Brose, D. A. Ramies, Y. Lee, D. Miles and S. I. Sherman, “Antitumor Activity of Cabozantinib (XL184) in a Cohort of Patients (pts) with Differentiated Thyroid Cancer (DTC).” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 5547.
[19]	P. Schoffski, R. Elisei, S. Muller, M. S. Brose, M. H. Shah, L. F. Licitra, B. Jarzab, V. Medvedev, M. Kreissl, B. Niederle, E. E. W. Cohen, L. J. Wirth, H. Y. Ali, C. Hessel, Y. Yaron, D. W. Ball, B. Nelkin, S. I. Sherman and M. Schlumberger, “An International, Double-Blind, Randomized, Placebo-Controlled Phase III Trial (EXAM) of Cabozantinib (XL184) in Medullary Thyroid Carcinoma (MTC) Patients (pts) with Documented RECIST Progression at Baseline.,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 5508.
[20]	C. Verslype, A. L. Cohn, R. K. Kelley, T. S. Yang, W. C. Su, D. A. Ramies, Y. Lee, X. Shen and E. Van Cutsem, “Activity of Cabozantinib (XL184) in Hepatocellular Carcinoma: Results from a Phase II Randomized Discontinuation Trial (RDT).” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4007.
[21]	E. P. Winer, S. Tolaney, H. Nechushtan, R. Berger, R. Kurzrock, I. G. Ron, P. Schoffski, A. Awada, C. A. Yasenchak, H. A. Burris, D. A. Ramies, T. Rafferty and X. Shen, “Activity of Cabozantinib (XL184) in Metastatic Breast Cancer (MBC): Results from a Phase II Randomized Discontinuation Trial (RDT),” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 535.
[22]	R. J. Buckanovich, R. Berger, A. Sella, B. I. Sikic, X. Shen, D. A. Ramies, D. C. Smith and I. B. Vergote, “Activity of Cabozantinib (XL184) in Advanced Ovarian Cancer Patients (pts): Results from a Phase II Randomized Discontinuation Trial (RDT),” Journal of Clinical Oncology, Vol. 29, 2011, Abstract No. 5008.
[23]	T. K. Choueiri, U. N. Vaishampayan, J. E. Rosenberg, T. Logan, A. L. Harzstark, B. I. Rini, S. Srinivas, L. M. Adams, L. J. Sherham, L. H. Ottesen, D. F. McDermott, D. Bottaro, W. M. Linehan and R. Srinivasan, “A Phase II and Biomarker Study (MET 111644) of the Dual Met/VEGFR-2 Inhibitor Foretinib in Patients with Sporadic and Hereditary Papillary Renal Cell Carcinoma: Final Efficacy, Safety, and PD Results,” Journal of Clinical Oncology, Vol. 30, No. 5S, 2012, Abstract No. 355.
[24]	B. J. Escudier, C. Porta, P. Bono, U. de Giorgi, O. Parikh, R. E. Hawkins, E. Sevin, S. Negrier, S. Khan, L. McCann, F. Mehmud and C. Cella, “Patient Preference between Pazopanib (Paz) and Sunitinib (Sun): Results of a Randomized Double-Blind, Placebo-Controlled, Cross-Over Study in Patients with Metastatic Renal Cell Carcinoma (mRCC)-PISCES Study, NCT 01064310,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. CRA-4502.
[25]	R. Motzer, T. E. Hutson, J. Reeves, R. Hawkins, J. Guo, P. Nathan, M. Staehler, P. de Souza, J. R. Merchan, K. Fife, J. Jin, R. Jones, H. Uemura, U. de Giorgi, U. Harmenberg, J. Wang, D. Cella, L. McCann, K. Deen and T. K. Choueiri, “Randomized, Open Label, Phase III Trial of Pazopanib versus Sunitinib in First-line Treatment of Patients with Metastatic Renal Cell Carcinoma (mRCC): Results of the COMPARZ Trial,” Acta Oncologica, Vol. 23, No. 9S, 2012, Abstract No. LBA8_PR.
[26]	C. Coppin, F. Porzsolt, A. Awa, J. Kumpf, A. Coldman and T. Wilt, “Immunotherapy for Advanced Renal Cell Cancer,” Cochrane Database of Systematic Reviews, No. 1, 2005, Article ID: CD001425.
[27]	J. J. Park, R. Omiya, Y. Matsumura, Y. Sakoda, A. Kuramasu, M. M. Augustine, S. Yao, F. Tsushima, H. Narazaki, S. Anand, Y. Liu, S. E. Strome, L. Chen and K. Tamada, “B7-H1/CD80 Interaction is Required for the Induction and Maintenance of Peripheral T-Cell Tolerance,” Blood, Vol. 116, No. 8, 2010, pp. 1291-1298. doi:10.1182/blood-2010-01-265975
[28]	R. H. Thompson, H. Dong, C. M. Lohse, B. C. Leibovich, M. L. Blute, J. C. Cheville and E. D. Kwon, “PD-1 is Expressed by Tumor-Infiltrating Immune Cells and is Associated with Poor Outcome For Patients With Renal Cell Carcinoma,” Clinical Cancer Research, Vol. 13, No. 6, 2007, pp. 1757-1761. doi:10.1158/1078-0432.CCR-06-2599
[29]	D. F. McDermott, C. G. Drake, M. Sznol, T. K. Choueiri, J. Powderly, D. C. Smith, J. Wigginton, D. McDonald, G. Kollia, A. K. Gupta and M. B. Atkins, “Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Previously Treated Metastatic Renal Cell Carcinoma (mRCC),” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4505.
[30]	S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton and M. Sznol, “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” The New England Journal of Medicine, Vol. 366, No. 26, 2012, pp. 2443-2454. doi:10.1056/NEJMoa1200690
[31]	B. I. Rini, J. Bellmunt, A. V. Alyzasova, J. Clancy, K. Wang, A. Niethammer and B. Escudier, “Randomized Phase IIIb Trial of Temsirolimus and Bevacizimab versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from INTORACT,” Annals of Oncology, Vol. 23, Suppl. 9, 2012, Abstract No. LBA21_PR.
[32]	T. Hutson, B. Escudier, E. Esteban, G. A. Bjarnason, H. Y. Lim, K. Pittman, P. Senico, A. Niethammer, D. Lu, S. Hariharan and R. Motzer, “Temsirolimus vs. Sorafenib as Second-Line Therapy in Metastatic Renal Cell Carcinoma: Phase 3 Results from the INTORSECT Trial,” Annals of Oncology, Vol. 23, Suppl. 9, 2012, Abstract No. LBA22_PR.
[33]	R. J. Motzer, B. Escudier, P. Tomczak, S. Negrier, M. E. Gore, J. Tarazi, S. Hariharan, B. Rosbrook, S. Kim and B. I. Rini, “Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors,” Annals of Oncology, Vol. 23, Suppl. 9, 2012, Abstract No. 793PD.
[34]	D. Y. C. Heng, T. K. Choueiri, J. L. Lee, L. C. Harshman, G. A. Bjarnason, J. J. Knox, M. J. MacKenzie, U. N. Vaishampayan, T. Yuasa, M. H. Tan, S. Y. Rha, F. Donskov, N. Agarwal, S. K. Pal, C. K. Kollmannsberger, S. A. North, B. I. Rini and L. Wood, “An In-Depth Multicentered Population-Based Analysis of Outcomes of Patients with Metastatic Renal Cell Carcinoma (mRCC) That Do Not Meet Eligibility Criteria For Clinical Trials,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4536.
[35]	C. Ferte, L. Albiges, J. C. Soria, Y. Loriot, K. Fizazi and B. J. Escudier, “The Use of Tumor Growth Rate (TGR) in Evaluating Sorafenib and Everolimus Treatment in mRCC Patients: An Integrated Analysis of the TARGET and RECORD Phase III Trials Data,” Journal of Clinical Oncology, Vol. 30, 2012, Abstract No. 4540.